NATIONAL INSTITUTES OF HEALTH

Kimberlyn Ellis, a graduate student in Human Genetics, has been selected as the 2024 Vanderbilt Prize Student Scholar, receiving a $1,000 cash prize and mentorship from Sarah Tishkoff, PhD. Ellis aims to bridge genomics, bioethics, and health policy for equitable precision medicine, focusing on chronic disease in populations with significant African ancestry.

A cancer vaccine effective at early lesion stage, not advanced tumors, suggests timing crucial for efficacy, according to Vanderbilt study. Vaccination boosts T cells, blocking tumor progression when immune checkpoint blockade fails.

University of Montana and Inimmune Corporation's cancer treatment compound, INI-4001, advances to human clinical trials in Australia, with potential for heroin and fentanyl addiction vaccine.

Senex Biotechnology secures European patent for SNX631-6, a CDK8/19 inhibitor for cancer treatment, complementing its US patent. The drug aims to address drug resistance and metastasis in various cancers, with plans for clinical trials in 2026.

Urine tests show promise in detecting various cancers, with ongoing research focusing on improving accuracy and expanding detection options, including for lung, ovarian, pancreatic, colorectal, prostate, bladder, and head and neck cancers.

Wockhardt's WCK 6777, a once-a-day β-lactam enhancer antibiotic, successfully completed Phase I study by NIH's DMID, showing promising safety profile. FDA granted Fast Track designation for cUTI and cIAI treatment. WCK 6777 is designed for outpatient-parenteral antimicrobial therapy, active against meropenem-resistant Gram negative pathogens, potentially reducing hospital admissions and costs.

The global Genotyping Market is projected to grow from USD 17.4 Billion in 2023 to USD 73.5 Billion by 2033, at a CAGR of 15.5%. Genotyping, using techniques like PCR and NGS, identifies genetic variations crucial for diagnostics, personalized medicine, and agriculture. Key applications include pharmacogenomics, diagnostics, and agricultural biotechnology. Ethical and privacy concerns are also highlighted.

Wockhardt Limited's WCK 6777 (Ertapenem/Zidebactam) granted Fast Track designation by USFDA for treating complicated urinary tract and intra-abdominal infections. Phase I study by NIH showed promising safety profile. Shares of Wockhardt Limited declined by 2.50% on NSE.

The SEAL trial, led by King’s and Evelina London, aims to prevent food allergies in babies with eczema by restoring skin barrier and managing inflammation. Participants, aged 0-12 weeks, will be treated with moisturiser twice daily and either standard steroid treatment during flare-ups or continuous use. The trial, funded by NIH and led by Harvard, will recruit 312 babies across four US sites, with Evelina London as the sole UK site.